Colivelin vs Davunetide (NAP/AL-108)
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Colivelin or Davunetide (NAP/AL-108)?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Colivelin and Davunetide (NAP/AL-108)?
Davunetide failed a well-powered human trial, providing definitive negative data; colivelin has never been tested in humans, so its therapeutic potential remains unknown rather than disproven.
Evidence Comparison
Davunetide (NAP) reached Phase 2/3 for progressive supranuclear palsy but failed its primary endpoint (Boxer 2014, Lancet Neurol). Colivelin is an ADNF/humanin chimera with rodent neuroprotection data only and zero human trials. Davunetide has stronger evidence by virtue of having been tested in humans, even though it failed.
Evidence Context Favoring Colivelin
Mechanistic research into ADNF-humanin hybrid neuroprotection pathways in animal models.
Evidence Context Favoring Davunetide (NAP/AL-108)
Research requiring human pharmacokinetic data or lessons from clinical trial failure in tauopathy.
Side-by-Side Snapshot
| Evidence grade | Colivelin: Level D Davunetide (NAP/AL-108): Level C |
|---|---|
| Research status | Colivelin: Preclinical Davunetide (NAP/AL-108): Phase 2 |
| Primary category | Colivelin: Cognitive & Nootropic Davunetide (NAP/AL-108): Cognitive & Nootropic |
| Cited studies | Colivelin: 2 Davunetide (NAP/AL-108): 3 |